Skip to main content
. Author manuscript; available in PMC: 2019 Nov 1.
Published in final edited form as: Neuropharmacology. 2018 Feb 27;142:231–239. doi: 10.1016/j.neuropharm.2018.02.028

Table 1.

Summary of binding data for N,N-diallyltryptamine (DALT) and ring-substituted derivatives at 33 receptors and transporters.

Site Speciesa Binding Affinity (Ki, nM)
DALT 5-MeO 5-F 5-Br 4-HO 4-AcO 2-Ph 5-MeO-2-Me 5-F-2-Me 7-Et
5-HT1A Human 100 19 80 11 319 383 402 267 318 1,013
5-HT1B Human > 10,000 735 1,787 950 2,494 > 10,000 273 2,267 2,011 > 10,000
5-HT1D Human 689 107 816 130 693 801 204 900 1,592 2,691
5-HT1E Human 378 500 474 512 238 467 > 10,000 1,594 1,273 > 10,000
5-HT2A Human 701 218 247 477 652 565 13 1,153 655 1,515
5-HT2B Human 61 59 16 53 2,593 63 192 241 17 65
5-HT2C Human 385 456 102 358 2,113 1,515 278 > 10,000 541 443
5-HT5A Human > 10,000 3,312 4,299 2,389 > 10,000 5,844 1,670 1,822 1,916 > 10,000
5-HT6 Human 1,718 153 74 133 213 1,791 68 206 168 > 10,000
5-HT7 Human > 10,000 90 402 49 600 724 > 10,000 > 10,000 493 > 10,000
SERT Human 150 499 36 127 5,210 1,089 > 10,000 > 10,000 983 795
α1A Human 1,663 > 10,000 1,251 637 > 10,000 > 10,000 75 1,198 1,570 > 10,000
α1B Human 1,369 > 10,000 > 10,000 2,050 > 10,000 > 10,000 904 > 10,000 > 10,000 > 10,000
α1D Human > 10,000 > 10,000 > 10,000 1,124 > 10,000 > 10,000 243 2,405 > 10,000 > 10,000
α2A Human 124 215 119 83 1,206 342 85 189 53 141
α2B Human 305 726 218 227 > 10,000 170 78 335 108 489
α2C Human 901 1,467 848 356 > 10,000 748 159 888 184 682
NET Human 1,121 > 10,000 1,818 964 > 10,000 > 10,000 420 > 10,000 > 10,000 1,879
D1 Human > 10,000 > 10,000 > 10,000 > 10,000 > 10,000 > 10,000 2,793 > 10,000 > 10,000 > 10,000
D2 Human > 10,000 > 10,000 2,463 4,349 > 10,000 > 10,000 388 > 10,000 4,416 > 10,000
D3 Human 672 > 10,000 120 240 1,570 > 10,000 342 2,399 414 1,082
D4 Human > 10,000 > 10,000 > 10,000 > 10,000 > 10,000 > 10,000 1,000 > 10,000 > 10,000 > 10,000
D5 Human > 10,000 > 10,000 > 10,000 > 10,000 > 10,000 > 10,000 2,003 > 10,000 > 10,000 > 10,000
DAT Human 1,406 3,378 2,150 2,455 > 10,000 > 10,000 746 2,413 2,208 1,725
MOR Human > 10,000 > 10,000 > 10,000 1,726 > 10,000 > 10,000 > 10,000 > 10,000 > 10,000 2,674
DOR Human > 10,000 > 10,000 > 10,000 > 10,000 > 10,000 > 10,000 6,789 > 10,000 > 10,000 > 10,000
KOR Human 2,477 1,132 2,184 898 > 10,000 5,235 589 391 580 580
PBR Rat kidneyb > 10,000 > 10,000 > 10,000 > 10,000 > 10,000 > 10,000 1,929 > 10,000 > 10,000 > 10,000
H1 Human 127 505 83 106 > 10,000 353 79 847 435 913
H2 Human > 10,000 > 10,000 > 10,000 > 10,000 > 10,000 > 10,000 367 > 10,000 > 10,000 > 10,000
H3 Guinea pig > 10,000 1,712 2,093 1,495 > 10,000 > 10,000 > 10,000 1,134 1,397 > 10,000
σ1 Rat brainb 101 301 86 101 2,765 299 > 10,000 427 531 22
σ2 Rat PC12b 356 253 303 224 > 10,000 > 10,000 717 1,235 396 136
a

The experiments were performed using cloned receptors from the species indicated.

b

The experiment was performed using tissues or cells natively expressing the receptor.

Abbreviations: 2-Ph, 2-phenyl-N,N-diallyltryptamine; 4-AcO, 4-acetoxy-N,N-diallyltryptamine; 4-HO, 4-hydroxy-N,N-diallyltryptamine; 5-Br, 5-bromo-N,N-diallyltryptamine; 5-F, 5-fluoro-N,N-diallyltryptamine; 5-F-2-Me, 5-methoxy-2-fluoro-N,N-diallyltryptamine; 5-MeO, 5-methoxy-N,N-diallyltryptamine; 5-MeO-2-Me, 5-methoxy-2-methyl-N,N-diallyltryptamine; 7-Et, 7-ethyl-N,N-diallyltryptamine; DALT, N,N-diallyltryptamine; DAT, dopamine transporter; DOR, δ-opioid receptor; KOR, κ-opioid receptor; MOR, μ-opioid receptor; NET, norepinephrine transporter; PBR, peripheral benzodiazepine receptor; SERT, serotonin transporter.

HHS Vulnerability Disclosure